Over the past decades, cervical cancer has been a worldwide public health problem. Population-based early cancer risk detection and prevention approaches, including vaccination, cytology screening and human papilloma virus (HPV) detection, with the aligned clinical management, have formed a well-rounded high-quality implementation system for cervical cancer control, and revolutionarily improved the quality of life of women: (1) the success of cervical cancer screening practices, (2) standardization of The Bethesda system for reporting cervicovaginal cytology, (3) improvement in the understanding of HPV pathogenesis in cervical cancer, and (4) the development of appropriate management approaches have significantly decreased the disease burden of cervical cancer worldwide. This scoping review aimed to understand the evolvement of cervical cancer screening and management guidelines, describe the Bethesda cervical cytology reporting system, and HPV vaccines and tests, and highlight the key information of present policies and practices.

Metastasis is a major factor associated with high recurrence and mortality in hepatocellular carcinoma (HCC) patients while the underlying mechanism of metastasis remains elusive. In our study, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) was shown to be involved in the process of metastasis in HCC.

The Cancer Genome Atlas (TCGA) database and HCC tissue microarrays were used to evaluate the expression of genes. In vitro migration, invasion, in vivo subcutaneous tumor model and in vivo lung metastasis assays were used to determine the role of PLOD2 in tumor growth and metastasis in HCC. RNA sequencing and gene set enrichment analysis were performed to uncover the downstream factor of PLOD2 in HCC cells. A luciferase reporter assay was performed to evaluate the interaction between PLOD2 and interferon regulatory factor 5 (IRF5).

The expression of PLOD2 in HCC tissues was higher than that in adjacent tissues, and increased PLOD2 expression was often found in advanced tumors and was correlated with poor prognosis in HCC patients. In vitro experiments, knockdown of PLOD2 reduced the migration and invasion of human HCC cells. Loss of PLOD2 suppressed human HCC growth and metastasis in a subcutaneous tumor model and a lung metastasis model. Baculoviral IAP repeat containing 3 (BIRC3) was proven to be the downstream factor of PLOD2 in human HCC cells. In addition, PLOD2 was transcriptionally regulated by IRF5 in HCC cells.

High expression of PLOD2 was regulated by IRF5, which was correlated with the poor survival of HCC patients. PLOD2 enhanced HCC metastasis via BIRC3, suggesting that PLOD2 might be a valuable prognostic biomarker for HCC treatment.

Restenosis is a serious complication after percutaneous coronary intervention (PCI) for patients with coronary heart disease (CHD). This prospective clinical study was designed to investigate the effects of liposomal prostaglandin E1 (lipo-PGE1) on coronary stenosis and restenosis.

Sixty patients diagnosed with CHD and scheduled for PCI surgery in Guangdong Hospital of Traditional Chinese Medicine were enrolled in this study. The patients were divided into either the Control group (n = 30) or lipo-PGE1 treatment group (PGE group) (n = 30). Restenosis after PCI was the primary outcome, and newly increased stenosis was the secondary outcome.

In total, 54 patients finished the follow-up and were included in the final analysis (n = 30 in the Control group and n = 24 in the PGE group). Baseline comparisons of stenosis location, stenosis degree, and the number of vessels in stenosis before PCI were comparable (P > 0.05). Comparisons of implanted stents showed similar features in stent diameter and stent length during PCI between the two groups (P > 0.05). For the primary outcome, there was no obvious difference in restenosis percentage (χ2 = 1.520, P = 0.615) nor number of vessels in restenosis (χ2 = 0.070, P = 0.791) in three arteries between groups. For the secondary outcome, although there was no significant difference in the number of non-culprit vessels in increased stenosis after PCI between groups (χ2 = 3.902, P = 0.272), the percentage of increased stenosis was much lower in the right coronary artery in the PGE group than the Control group (U = 263.0, P = 0.048).

Lipo-PGE1 does not affect restenosis after PCI, but it may be effective in ameliorating newly increased stenosis in arteries.

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterised by cognitive impairment and numerous pathologies, including β-amyloid (Aβ) and Tau proteopathies, altered immune responses, and brain atrophy. Despite hundreds of years of investigations into its underlying pathogenesis, the aetiology of AD is not clearly understood. AD diagnostic criteria are not effective at identifying pre-clinical patients and current AD treatments cannot postpone or reverse disease progression. The development of non-human primate (NHP) models of AD is urgently required due to their close phylogenetic relationship to humans, similar neuroanatomy, comparable genetics, and high complexity of high-order cognitive functions, making them a better model of AD than rodents. We compared and contrasted AD-associated pathological features and behavioural alterations manifested between naturally aged spontaneous and induced NHP models of AD. Induced models of AD can be established using injections of Aβ oligomers, brain homogenates, neurotoxins, or formaldehyde. In recent decades, both spontaneous and induced NHP models of AD have been used to facilitate the development of neuroimaging tracers and therapeutic treatments, aiding in the translational application of lab discoveries into clinical trials involving human subjects. The establishment of a standardised NHP model of AD is expected by making a guideline concerning NHP species, types and doses of inducers, frequency of injections, and duration of inoculation. Its development can be facilitated by a comprehensive assessment of NHPs, including all AD-associated pathologies and a wide range of behavioural examinations. NHP models of AD have contributed to AD research and their evolution is expected to better recapitulate AD features and present greater translational potential in the near future.

Prolyl endopeptidase (PREP) is a serine endopeptidase that participates in many pathological processes including inflammation, oxidative stress, and autophagy. Our previous studies found that PREP knockout exhibited multiple benefits in high-fat diet (HFD) or methionine choline-deficient diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD). However, cumulative studies have suggested that PREP performs complex functions during disease development. Therefore, further understanding the role of PREP in MAFLD development is the foundation of PREP intervention.

In this study, an HFD-induced MAFLD model at different time points (4, 8, 12, and 16 weeks) was used to explore dynamic changes in the PREP proline-glycine-proline (PGP)/N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) system. To explore its potential value in MAFLD treatment, saline, or the PREP inhibitor, KYP-2047, was administered to HFD-induced MAFLD mice from the 10th to 16th weeks.

PREP activity and expression were increased in HFD-mice compared with control mice from the 12th week onwards, and increased PREP mainly resulted in the activation of the matrix metalloproteinase 8/9 (MMP8/9)-PREP-PGP axis rather than the thymosin β4-meprin α/PREP-AcSDKP axis. In addition, KYP-2047 reduced HFD-induced liver injury and oxidative stress, improved lipid metabolism through the suppression of lipogenic genes and the induction of β-oxidation-related genes, and attenuated hepatic inflammation by decreasing MMP8/9 and PGP. Moreover, KYP2047 restored HFD-induced impaired autophagy and this was verified in HepG2 cells.

These findings suggest that increased PREP activity/expression during MAFLD development might be a key factor in the transition from simple steatosis to steatohepatitis, and KYP-2047 might possess therapeutic potential for MAFLD treatment.

Primary sclerosing cholangitis (PSC) is an orphan, cholestatic liver disease that is characterized by inflammatory biliary strictures with variable progression to end-stage liver disease. Its pathophysiology is poorly understood. Chronic biliary inflammation is likely driven by immune dysregulation, gut dysbiosis, and environmental exposures resulting in gut-liver crosstalk and bile acid metabolism disturbances. There is no proven medical therapy that alters disease progression in PSC, with the commonly prescribed ursodeoxycholic acid being shown to improve liver biochemistry at low-moderate doses (15–23 mg/kg/day) but not alter transplant-free survival or liver-related outcomes. Liver transplantation is the only option for patients who develop end-stage liver disease or refractory complications of PSC. Immunosuppressive and antifibrotic agents have not proven to be effective, but there is promise for manipulation of the gut microbiome with fecal microbiota transplantation and antibiotics. Bile acid manipulation via alternate synthetic bile acids such as norursodeoxycholic acid, or interaction at a transcriptional level via nuclear receptor agonists and fibrates have shown potential in phase II trials in PSC with several leading to larger phase III trials. In view of the enhanced malignancy risk, statins, and aspirin show potential for reducing the risk of colorectal cancer and cholangiocarcinoma in PSC patients. For patients who develop clinically relevant strictures with cholestatic symptoms and worsening liver function, balloon dilatation is safer compared with biliary stent insertion with equivalent clinical efficacy.

Diabetes mellitus (DM) is an established risk for biliary tract cancer (BTC). Metformin, an anti-diabetes medication, has been reported for its association with a reduced risk of BTC. However, the controversy about metformin’s benefit among epidemiological studies is unresolved. This study is to investigate metformin’s effects on the development and progression of BTC.

Literature searches were performed, without language restriction, in Pubmed, Embase, and Web of Science, from their respective inceptions to February 28, 2023. All studies were screened by two researchers using Covidence. Quality assessment was performed using the Newcastle-Ottawa Scale. Meta-analyses were performed by a fixed and random-effect model using RevMan version 5.4.

Nine observational studies met the inclusion criteria and were included in the meta-analysis. With pooled samples of 24,743,526 individuals from 4 case-control and 2 cohort studies, metformin was not associated with a decreased risk of BTC (pooled RR: 0.82, 95% CI: 0.42–1.59, p = 0.56). Sub-group analyses in each study design also revealed a null effect of metformin. Meta-analysis of 3 cohort studies reporting the association between metformin and survival of patients with BTC with a pooled sample of 1,163 patients showed a marginally significant effect of metformin on survival outcome improvement in both fixed effect models (pooled RR: 0.83, 95% CI: 0.68–1.00, p = 0.05), and random-effect model (pooled RR: 0.83, 95% CI: 0.68–1.01, p = 0.07).

Meta-analyses of available observational studies show that metformin was neither significantly associated with decreased risk nor, survival improvement for BTC patients who had DM.

Nonalcoholic fatty liver disease (NAFLD) has become one of the most common and important chronic liver diseases worldwide. Some chronic infectious diseases are associated with the risk of NAFLD. These can induce abnormal glucose and lipid metabolism, insulin resistance, inflammatory activation and other responses, which increase the risk of progression of liver fibrosis. The present study describes the pathogenesis and management of NAFLD with chronic infectious diseases, such as hepatitis B virus, hepatitis C virus, Helicobacter pylori, and human immunodeficiency virus infections.

There is a lack of data supporting the notion that antiviral treatments can benefit children with chronic hepatitis B (CHB) having high viremia and normal or mildly elevated serum alanine aminotransferase (ALT) levels. We aimed to analyze the efficacy of antiviral treatments in children with CHB and explore the factors associated with functional cure.

Forty-eight children with CHB having high viremia and normal or mildly elevated serum ALT levels were screened in this real-world study. Thirty-two children received either interferon-alpha (IFN-α) monotherapy, IFN-α therapy with a nucleoside analog (NA) add-on, or IFN-α and NA combination therapy. The 16 children in the control group did not receive antiviral treatment. All 48 children were available for follow-up assessments for the entire 36-month study period. We identified a functional cure with respect to hepatitis B virus (HBV) DNA loss, loss /seroconversion of circulating hepatitis B e antigen (HBeAg), and loss of hepatitis B surface antigen (HBsAg) with or without seroconversion. Cox regression analysis was employed to evaluate the factors that may have influenced the functional cure.

After 36 months, the cumulative functional cure rate was 56.25% (18/32) in the treated group and 0% (0/16) in the control group (p<0.001). In the treated group, the serum HBV DNA levels declined rapidly at the end of a 6-month visit and the cured children achieved a loss rate of 100% (18/18) within 16 months of beginning treatment, compared with 64.29% (9/14) of the uncured children (p<0.001). The rates of HBeAg seroconversion were significantly higher among the cured children than among the uncured children (p<0.001). All 16 children in the control group maintained high levels of serum HBV DNA and were positive for both serum HBeAg and HBsAg during the entire 36 months of the study period. Functional cure was associated with younger ages (1–6 vs. 7–14 years, p=0.013), CD8+ T lymphocyte counts (p=0.013), and B lymphocyte counts (p=0.003). No serious adverse events were observed.

Antiviral treatment achieved a functional cure of CHB in a high proportion of children having high-level viremia and normal or mildly elevated ALT levels. Younger age and high peripheral lymphocyte counts were associated with this functional cure.

Hepatocellular carcinoma (HCC) is a common malignant tumor with high incidence and cancer mortality worldwide. Post-translational modifications (PTMs) of proteins have a great impact on protein function. Almost all proteins can undergo PTMs, including phosphorylation, acetylation, methylation, glycosylation, ubiquitination, and so on. Many studies have shown that PTMs are related to the occurrence and development of cancers. The findings provide novel therapeutic targets for cancers, such as glypican-3 and mucin-1. Other clinical implications are also found in the studies of PTMs. Diagnostic or prognostic value, and response to therapy have been identified. In HCC, it has been shown that glycosylated alpha-fetoprotein (AFP) has a higher detection rate for early liver cancer than conventional AFP. In this review, we mainly focused on the diagnostic and prognostic value of PTM, in order to provide new insights into the clinical implication of PTM in HCC.

The clinicopathological features and long-term outcomes of patients with vanishing bile duct syndrome (VBDS) have yet to be elucidated. The study aims to investigate these features and identify factors associated with poor prognosis.

This multicenter retrospective study recruited patients with liver biopsy-proven VBDS who were followed up at five hospitals in northern China from January 2003 to April 2022. Clinical and pathological data at time of biopsy were reviewed. Clinical outcomes including cirrhosis, decompensation events, liver transplantation (LT), and liver-related death were recorded. Cox regression analysis was used to identify the risk factors associated with poor outcomes.

A total of 183 patients were included. The median age was 47 years, with 77.6% being women. During a median follow-up of 4.8 years, 88 patients developed compensated or decompensated cirrhosis, 27 died, and 15 received LT. Multivariate Cox regression analysis showed that hepatocellular cholestasis (HR 2.953, 95% CI: 1.437–6.069), foam cells (HR 2.349, 95% CI: 1.092–5.053), and advanced fibrosis (HR 2.524, 95% CI: 1.313–4.851) were independent predictors of LT or liver-related deaths. A nomogram formulated with the above factors showed good consistency with a concordance index of 0.746 (95% CI: 0.706–0.785).

Nearly half of VBDS patients studied progressed to end-stage liver disease and 23% of them had LT or liver-related death within two years of diagnosis. Hepatocellular cholestasis, foam cells and advanced fibrosis rather than the degree of bile duct loss or underlying etiologies were independently associated with poor prognosis in VBDS patients.

Zuojin Pill (ZJP) is a classic Chinese herbal prescription with good efficacy in the treatment of Anxiety disorder (AD) and Major depressive disorder (MDD). Nevertheless, the potential mechanisms of ZJP remain unclear. Based on network pharmacology and molecular docking methods, this study aims to elucidate the possible mechanism of ZJP in the treatment of AD and MDD.

The components and targets of Rhizoma Coptidis and Fructus Evodiae were collected from TCMSP, ETCM, HERB, SWISSADME and STITCH databases. The disease targets related to MDD and AD were collected from DISGENET, GENECARDS and OMIM databases. Protein-protein interaction network was constructed by STRING database, GO and KEGG enrichment analysis was performed by METASCAPE database, and "drugs-components-targets network" was constructed by Cytoscape software. Molecular docking verification was performed by Sailvina2.0 software.

ZJP may act on AKT1, IL6, TNF and other targets through caffeine, isorhamnetin, berberine and other components, regulating the Inflammatory mediator regulation of TRP channels, Serotonergic synapse, Dopaminergic synapse, PI3K/AKT signaling pathway, and other pathways. The results of molecular docking showed that berberine had the best binding activity with the core target.

ZJP can exert anti-anxiety and anti-depression effects through multiple components, multiple targets and multiple pathways.

Numerous clinical studies over recent years have reported an inverse relationship between benign prostatic hyperplasia (BPH) size and the incidence of prostate cancer (PCa), leading to the clinical hypothesis that the expanding BPH zone damages the glandular tissue where PCa predominately develops. This systematic review aims to establish a historical basis and reference on the zonal origin of BPH and prostate cancer (PCa) within the prostate.

Using the PRISMA guidelines, an in-depth review was conducted of studies published in the PubMed database between January 1978 and November 2022. Due to clinical heterogeneity in type of study designs, meta-analysis was not possible, and a narrative review approach was adopted.

Thirty-eight studies met the inclusion criteria, all of which showed that BPH predominantly develops within the transition zone (TZ) and that PCa predominantly develops in the peripheral zone (PZ) of the prostate respectively. This report provides a systemic overview of the historical evolution on the concept of zonal origin for BPH and PCa. The listed studies support the current clinical understanding that BPH mainly originates in the TZ and that the majority of PCa originates in the PZ of the prostate.

To our knowledge, this is the first systemic review on the zonal origin of BPH and PCa and is an important step in the context of evidence-based medicine. This review should encourage other clinicians and investigators to further study the dynamic interactions between the different prostate zones, in particular between the TZ and the PZ, and whether BPH size may be protective against development of PCa.

To evaluate the efficacy and safety of different Chinese herbal compounds combined with Entecavir in the treatment of hepatitis B cirrhosis during the compensatory period by using mesh meta-analysis.

PubMed, CNKI, Wanfang and VIP databases were searched by computer, and the retrieval time was from the establishment of each database to October 5, 2022. According to inclusion and exclusion criteria, literature search was conducted independently by two researchers. RevMan5.4.1 software provided by Cochrane was used for evaluation, and Stata16.0 software was used for statistical analysis.

A total of 34 RCTs were included, involving 16 TCM compounds and 1543 patients. The results of network meta-analysis showed that ALT indexes of liver function were listed as Yiqi Jiedu Tongluo Method>Luoshugan Tablet>Anluo Huaxian Wan>Qishenrugan Capsule>Qingganhuaji Decoction>Ganshuang Granules>Compound Biejia Rugan Tablet>Rougan Sanjie Decoction>Shugan Jianpi Decoction>Shenqi Fuzheng Huayu Decoction>Peituhua Decoction>Shugan Jianpi Huoxu prescription>Rhubarb Zhezhan Capsule combined with Entecavir treatment respectively; The order of HA index of liver fibrosis was Heluo Shugan Tablet>Shugan Jianpi Huoxui prescription>Anluo Huaxian Wan>Compound Biejia Ruangan Tablet>Rougan Sanjie Decoction>Ganshuang Granules>Danji Huoxui Decoction>Yiqi Jiedu Tongluo Method>Rhubarb Zhezhe Capsule>Fuzheng Huayu Table>Shugan Jianpi Decoction>Rougan Huayu Decoction>Peitu Huayu Decoction>Qingganhuaji Prescription>Shenqi Fuzheng Huayu prescription combined with Entecavir respectively; In order of adverse reactions from best to worst, Shuganjianpi Decoction, Qishenrugangan Capsule, Ganshuang Granules, Peituhuazhi Decoction, compound Biejiruganpian, and He Shugan Pian combined with entecavir, respectively; The effective rate of treatment was listed as Ganshuang Granules>Compound Biejia Ruangan Tablets>uoshugan Tablets>Rougansanjie Decoction>Rhubarb Zhezhe Capsules>Yiqi Jiedu Tongluo Method>Qingganhuaji prescription>Anluo Huaxia Wan>Shugan Jianpi Decoction>Fuzheng Huayu tablets>Peituhuazhi Decoction>Shenqi Fuzheng Huayu prescription combined with Entecavir respectively.

Entecavir combined with supplementing qi and detoxifying and dredging collages is the best method to recover ALT index of liver function during the compensation period for hepatitis B cirrhosis; Entecavir combination and Luoshugan tablet were the best treatment for HA index of hepatic fibrosis; Entecavir combined with Shuganjianpi Decoction was the best treatment for adverse reactions; The best treatment efficiency was Entecavir combined with Ganshuang granules.

To classify the subtypes of metabolic-associated fatty liver disease (MAFLD) and provide new insights into the heterogeneity of MAFLD.

Electronic medical records (EMR) of MAFLD diagnosed in accordance with the diagnostic criteria of Hubei Provincial Hospital of Traditional Chinese Medicine from 2016–2020 were included in the study. for physical annotation, and the data on each clinical phenotype was normalized according to corresponding aspirational standards. The MAFLD heterogeneous medical record network (HEMnet) was constructed using sex, age, disease diagnosis, symptoms, and Western medicine prescriptions as nodes and the co-occurrence times between phenotypes as edges. K-means clustering was used for disease classification. Relative risk (RR) was used to assess the specificity of each phenotype. Statistical methods were used to compare differences in laboratory indicators among subtypes.

A total of patients (12,626) with a mean age of 55.02 (±14.21) years were included in the study. MAFLD can be divided into five subtypes: digestive diseases (C0), mental disorders and gynecological diseases (C1), chronic liver diseases and decompensated complications (C2), diabetes mellitus and its complications (C3), and immune joint system diseases (C4).

Patients with MAFLD experience various symptoms and complications. The classification of MAFLD based on the HEMnet method is highly reliable.

Liver stiffness measurement (LSM) may effectively correlate to the presence of liver fibrosis, but it is controversial to use for the prediction of clinical outcomes. Therefore, we aimed to evaluate the predictive value of liver stiffness for the regression of liver fibrosis.

In this study, we collected data from a clinical cohort of patients who are received anti-virus therapies for 48 weeks. 180 naive chronic hepatitis B (CHB) patients, who received paired LSM and liver biopsy with pre- and post-treatments were analyzed. Two methods (FibroScan and iLivTouch) test LSM.

The area under the receiver operating characteristics curve (AUROC) of changing LSM for fibrosis regression is higher in advanced fibrosis patients (F5/6) than in moderate fibrosis patients (F3/4) in both FibroScan (0.719, 95%CI, 0.590–0.848; P=0.003; vs 0.617, 95%CI, 0.379–0.856, P=0.282) and iLivTouch (0.707, 95%CI, 0.567–0.847; P=0.011; vs 0.583, 95%CI, 0.422–0.744; P=0.377). A higher kappa value was received in advanced stage than in moderate stage both in FibroScan (0.392, P=0.001 vs 0.265, P=0.053) and iLivTouch (0.326, P=0.019 vs 0.030, P=0.833). Cut-off set as 4.10 kPa (sen, 69.4%; spe, 73.9%) in FibroScan, as 4.25 kPa (sen, 56.8%; spe, 72.2%) in iLivTouch.

The changing LSM can be used for predicting the liver fibrosis regression in advanced stage of CHB patients.

This study aimed to evaluate the effect of coconut oil (CO) on steatosis and oxidative stress in rats fed a high-fat diet.

Three groups of male Wistar rats were used: the control group (CG, n = 10) received a standard diet for 50 days, the hyperlipidic group (HL, n = 10) received a high-fat diet with 50% lard for 50 days, and the hyperlipidic-CO group (HL+CO, n = 10) received a high-fat diet with 50% lard for 30 days followed by 25% lard and 25% CO for 20 days. Then, the animals were euthanized, and their blood, liver, and adipose tissue were collected for biochemical analyses.

The groups that received a high-fat diet had pronounced liver steatosis. Compared to the CG and HL groups, the HL+CO group had less weight gain, but liver fat and triglycerides were increased, with a significant reduction in liver cholesterol. Glutathione increased significantly and vitamin E decreased in the livers of the experimental groups compared to the control. Lipid peroxidation in the serum and liver was less in the HL+CO group compared to that in the HL group, but it was higher than that in the control group. CO caused significant accumulation of hepatic fat, triglycerides, and fat content, despite decreasing the hepatic cholesterol levels. There was a better hepatic antioxidant response in the CO group, especially compared with the HL group.

CO was not able to prevent or improve liver fat levels, but the HL+CO group had a better antioxidant profile. Additional clinical studies are necessary to verify the efficacy and safety of different CO doses on both hepatic and lipid metabolism.

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease, affecting a quarter of the world’s population. The spectrum of NAFLD ranges from simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and ultimately to hepatocellular carcinoma (HCC). Multiple factors are involved in the pathogenesis and progression of NAFLD, wherein genetic, epigenetic, environmental, gut-microbiome, and dietary factors play a substantial role. Robust genome-wide association studies (GWAS) have recently identified several genetic alterations contributing to NAFLD progression to liver cancer. This review describes the most critical genetic variations identified in various genes that modulate NAFLD pathogenesis. As expected, NAFLD shows gene variations that regulate or influence hepatocyte lipid metabolism. In addition to polymorphisms in genes that regulate insulin signaling, fibrosis, inflammation, and oxidative stress, cytokine/chemokine-expressing genes also participate in NAFLD pathogenesis. GWAS helped us distinguish genetic polymorphisms that modulate steatosis, fibrosis, or both in NAFLD patients. Identifying genetic factors predisposing an individual to NAFLD helps stratify people at high risk and aids in imparting preventive strategies early in life. Such studies should also help in adopting prevention strategies and targeted treatment regimes.